About MyoKardia
MyoKardia is a company based in San Francisco (United States) founded in 2012 was acquired by Bristol-Myers Squibb in October 2020.. MyoKardia has raised $98 million across 5 funding rounds from investors including JPMorgan Chase, Sanofi and Bristol-Myers Squibb. The company has 224 employees as of December 31, 2019. MyoKardia operates in a competitive market with competitors including Tenaya Therapeutics, Cellino, Eiger BioPharmaceuticals, Arrakis Therapeutics and Capricor Therapeutics, among others.
- Headquarter San Francisco, United States
- Employees 224 as on 31 Dec, 2019
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Myokardia Inc
-
Annual Revenue
$33.56 M193as on Dec 31, 2018
-
Net Profit
$-276.21 M-308as on Dec 31, 2019
-
EBITDA
$-287.83 M-291as on Dec 31, 2019
-
Total Equity Funding
$98 M (USD)
in 5 rounds
-
Latest Funding Round
-
Investors
JPMorgan Chase
& 5 more
-
Employee Count
224
as on Dec 31, 2019
-
Acquired by
Bristol-Myers Squibb
(Oct 05, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Leadership Team
394 people
Software Development Team
340 people
Senior Team
99 people
Product Management Team
97 people
Operations Team
83 people
Data Analysis and Operations Team
60 people
Sales and Marketing
58 people
Human Resources and Administration
45 people
Unlock access to complete
Funding Insights of MyoKardia
MyoKardia has successfully raised a total of $98M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Last Round
-
First Round
First Round
(20 Sep 2012)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2016 | Amount | Post-IPO - MyoKardia | Valuation |
investors |
|
| Apr, 2015 | Amount | Series B - MyoKardia | Valuation | Casdin Capital , Sanofi |
|
| Aug, 2014 | Amount | Series B - MyoKardia | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in MyoKardia
MyoKardia has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include JPMorgan Chase, Sanofi and Bristol-Myers Squibb. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Founded Year | Domain | Location | |
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Venture capital funding is provided to early-stage life science companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by MyoKardia
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - MyoKardia
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Myokardia Comparisons
Competitors of MyoKardia
MyoKardia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Cellino, Eiger BioPharmaceuticals, Arrakis Therapeutics and Capricor Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| domain | founded_year | HQ Location |
Developer of autologous cell therapies
|
|
| domain | founded_year | HQ Location |
Developer of antiviral agents against targets in the treatment of hepatitis
|
|
| domain | founded_year | HQ Location |
Provider of tools for the analysis of RNA structures
|
|
| domain | founded_year | HQ Location |
Regenerative medicine for cardiovascular disorders is developed using cell-based platforms.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Myokardia
Frequently Asked Questions about MyoKardia
When was MyoKardia founded?
MyoKardia was founded in 2012.
Where is MyoKardia located?
MyoKardia is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is MyoKardia a funded company?
MyoKardia is a funded company, having raised a total of $98M across 5 funding rounds to date. The company's 1st funding round was a Series B of $10M, raised on Sep 20, 2012.
How many employees does MyoKardia have?
As of Dec 31, 2019, the latest employee count at MyoKardia is 224.
What is the annual revenue of MyoKardia?
Annual revenue of MyoKardia is $33.56M as on Dec 31, 2018.
What does MyoKardia do?
MyoKardia was founded in 2012 in San Francisco, United States, within the biotechnology sector. Operations center on creating therapies for cardiovascular conditions, including hypertrophic and dilated cardiomyopathy. A candidate treatment, MYK-224, targets cardiac myosin to limit excessive cross-bridge formation in hypertrophic cardiomyopathy. This mechanism seeks to control contractility, support relaxation, and lower variability in drug kinetics compared to prior options.
Who are the top competitors of MyoKardia?
MyoKardia's top competitors include Esperion Therapeutics, Tenaya Therapeutics and Cellino.
Who are MyoKardia's investors?
MyoKardia has 6 investors. Key investors include JPMorgan Chase, Sanofi, Bristol-Myers Squibb, Perceptive Advisors, and Casdin Capital.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.